Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant

The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bival...

Full description

Saved in:
Bibliographic Details
Published inbioRxiv
Main Authors Scheaffer, Suzanne M, Lee, Diana, Whitener, Bradley, Ying, Baoling, Wu, Kai, Jani, Hardik, Martin, Philippa, Amato, Nicholas J, Avena, Laura E, Berrueta, Daniela Montes, Schmidt, Stephen D, O'Dell, Sijy, Nasir, Arshan, Chuang, Gwo-Yu, Stewart-Jones, Guillaume, Koup, Richard A, Doria-Rose, Nicole A, Carfi, Andrea, Elbashir, Sayda M, Thackray, Larissa B, Edwards, Darin K, Diamond, Michael S
Format Journal Article Paper
LanguageEnglish
Published United States Cold Spring Harbor Laboratory 13.09.2022
Edition1.1
Subjects
Microbiology
Online AccessGet full text

Cover

Abstract The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bivalent vaccines that encode for spike proteins from both historical and newly-emerged variant strains. Here, we evaluated the immunogenicity and protective efficacy of two bivalent vaccines that recently were authorized for use in Europe and the United States and contain two mRNAs encoding Wuhan-1 and either BA.1 (mRNA-1273.214) or BA.4/5 (mRNA-1273.222) spike proteins. As a primary immunization series in BALB/c mice, both bivalent vaccines induced broader neutralizing antibody responses than the constituent monovalent vaccines (mRNA-1273 [Wuhan-1], mRNA-1273.529 [BA.1], and mRNA-1273-045 [BA.4/5]). When administered to K18-hACE2 transgenic mice as a booster at 7 months after the primary vaccination series with mRNA-1273, the bivalent vaccines induced greater breadth and magnitude of neutralizing antibodies compared to an mRNA-1273 booster. Moreover, the response in bivalent vaccine-boosted mice was associated with increased protection against BA.5 infection and inflammation in the lung. Thus, boosting with bivalent Omicron-based mRNA-1273.214 or mRNA-1273.222 vaccines enhances immunogenicity and protection against currently circulating SARS-CoV-2 strains.
AbstractList The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bivalent vaccines that encode for spike proteins from both historical and newly-emerged variant strains. Here, we evaluated the immunogenicity and protective efficacy of two bivalent vaccines that recently were authorized for use in Europe and the United States and contain two mRNAs encoding Wuhan-1 and either BA.1 (mRNA-1273.214) or BA.4/5 (mRNA-1273.222) spike proteins. As a primary immunization series in BALB/c mice, both bivalent vaccines induced broader neutralizing antibody responses than the constituent monovalent vaccines (mRNA-1273 [Wuhan-1], mRNA-1273.529 [BA.1], and mRNA-1273-045 [BA.4/5]). When administered to K18-hACE2 transgenic mice as a booster at 7 months after the primary vaccination series with mRNA-1273, the bivalent vaccines induced greater breadth and magnitude of neutralizing antibodies compared to an mRNA-1273 booster. Moreover, the response in bivalent vaccine-boosted mice was associated with increased protection against BA.5 infection and inflammation in the lung. Thus, boosting with bivalent Omicron-based mRNA-1273.214 or mRNA-1273.222 vaccines enhances immunogenicity and protection against currently circulating SARS-CoV-2 strains.
The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bivalent vaccines that encode for spike proteins from both historical and newly-emerged variant strains. Here, we evaluated the immunogenicity and protective efficacy of two bivalent vaccines that recently were authorized for use in Europe and the United States and contain two mRNAs encoding Wuhan-1 and either BA.1 (mRNA-1273.214) or BA.4/5 (mRNA-1273.222) spike proteins. As a primary immunization series in BALB/c mice, both bivalent vaccines induced broader neutralizing antibody responses than the constituent monovalent vaccines (mRNA-1273 [Wuhan-1], mRNA-1273.529 [BA.1], and mRNA-1273-045 [BA.4/5]). When administered to K18-hACE2 transgenic mice as a booster at 7 months after the primary vaccination series with mRNA-1273, the bivalent vaccines induced greater breadth and magnitude of neutralizing antibodies compared to an mRNA-1273 booster. Moreover, the response in bivalent vaccine-boosted mice was associated with increased protection against BA.5 infection and inflammation in the lung. Thus, boosting with bivalent Omicron-based mRNA-1273.214 or mRNA-1273.222 vaccines enhances immunogenicity and protection against currently circulating SARS-CoV-2 strains.The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has resulted in diminished vaccine efficacy and persistent transmission. One strategy to broaden vaccine-induced immunity is to administer bivalent vaccines that encode for spike proteins from both historical and newly-emerged variant strains. Here, we evaluated the immunogenicity and protective efficacy of two bivalent vaccines that recently were authorized for use in Europe and the United States and contain two mRNAs encoding Wuhan-1 and either BA.1 (mRNA-1273.214) or BA.4/5 (mRNA-1273.222) spike proteins. As a primary immunization series in BALB/c mice, both bivalent vaccines induced broader neutralizing antibody responses than the constituent monovalent vaccines (mRNA-1273 [Wuhan-1], mRNA-1273.529 [BA.1], and mRNA-1273-045 [BA.4/5]). When administered to K18-hACE2 transgenic mice as a booster at 7 months after the primary vaccination series with mRNA-1273, the bivalent vaccines induced greater breadth and magnitude of neutralizing antibodies compared to an mRNA-1273 booster. Moreover, the response in bivalent vaccine-boosted mice was associated with increased protection against BA.5 infection and inflammation in the lung. Thus, boosting with bivalent Omicron-based mRNA-1273.214 or mRNA-1273.222 vaccines enhances immunogenicity and protection against currently circulating SARS-CoV-2 strains.
Author Wu, Kai
Scheaffer, Suzanne M
Nasir, Arshan
Whitener, Bradley
Martin, Philippa
Berrueta, Daniela Montes
Stewart-Jones, Guillaume
Carfi, Andrea
Thackray, Larissa B
Lee, Diana
Avena, Laura E
Chuang, Gwo-Yu
Schmidt, Stephen D
Elbashir, Sayda M
Jani, Hardik
O'Dell, Sijy
Koup, Richard A
Amato, Nicholas J
Edwards, Darin K
Doria-Rose, Nicole A
Diamond, Michael S
Ying, Baoling
Author_xml – sequence: 1
  givenname: Suzanne M
  surname: Scheaffer
  fullname: Scheaffer, Suzanne M
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
– sequence: 2
  givenname: Diana
  surname: Lee
  fullname: Lee, Diana
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 3
  givenname: Bradley
  surname: Whitener
  fullname: Whitener, Bradley
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
– sequence: 4
  givenname: Baoling
  surname: Ying
  fullname: Ying, Baoling
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
– sequence: 5
  givenname: Kai
  surname: Wu
  fullname: Wu, Kai
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 6
  givenname: Hardik
  surname: Jani
  fullname: Jani, Hardik
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 7
  givenname: Philippa
  surname: Martin
  fullname: Martin, Philippa
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 8
  givenname: Nicholas J
  surname: Amato
  fullname: Amato, Nicholas J
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 9
  givenname: Laura E
  surname: Avena
  fullname: Avena, Laura E
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 10
  givenname: Daniela Montes
  surname: Berrueta
  fullname: Berrueta, Daniela Montes
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 11
  givenname: Stephen D
  surname: Schmidt
  fullname: Schmidt, Stephen D
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
– sequence: 12
  givenname: Sijy
  surname: O'Dell
  fullname: O'Dell, Sijy
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
– sequence: 13
  givenname: Arshan
  surname: Nasir
  fullname: Nasir, Arshan
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 14
  givenname: Gwo-Yu
  surname: Chuang
  fullname: Chuang, Gwo-Yu
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 15
  givenname: Guillaume
  surname: Stewart-Jones
  fullname: Stewart-Jones, Guillaume
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 16
  givenname: Richard A
  surname: Koup
  fullname: Koup, Richard A
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
– sequence: 17
  givenname: Nicole A
  surname: Doria-Rose
  fullname: Doria-Rose, Nicole A
  organization: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA
– sequence: 18
  givenname: Andrea
  surname: Carfi
  fullname: Carfi, Andrea
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 19
  givenname: Sayda M
  surname: Elbashir
  fullname: Elbashir, Sayda M
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 20
  givenname: Larissa B
  surname: Thackray
  fullname: Thackray, Larissa B
  organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA
– sequence: 21
  givenname: Darin K
  surname: Edwards
  fullname: Edwards, Darin K
  organization: Moderna, Inc., Cambridge MA, USA
– sequence: 22
  givenname: Michael S
  surname: Diamond
  fullname: Diamond, Michael S
  organization: Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, Saint Louis, MO, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36263060$$D View this record in MEDLINE/PubMed
BookMark eNpNkMtOwzAURC1URMvjA9ggL9kk2DeOkyxLxUuqQKLANrpxbGqUOBA7FfD1tCqv1cziaKQ5-2TkOqcJOeYs5pzxM2AAMStiDnHKMsnFDpmALCDKgaWjf31Mjrx_YYxBIXmSiT0yTiTIhEk2IW_ndoWNdoEupveLaNY9RUDb-9spXaFS1mlPrVO9Rq9ptY46LGlnqNND6LGxnxhs5yi6mr72XdAqUHxG63ygYanp-TRO6V1rVb-GVthbdOGQ7BpsvD76zgPyeHnxMLuO5ndXN7PpPKogTUQkWaalSA2IAhODuQKtpAJe1yIXiFhJlaYoM2EKnhtW5AbSgkFeARjOtUkOyOl2t7Jd_25X5WtvW-w_yo24khUlh3Ir7g9df3gbtA9la73STYNOd4MvIdvIFCzboCff6FC1uv4d_TGafAF9nnfr
ContentType Journal Article
Paper
Copyright 2022, Posted by Cold Spring Harbor Laboratory
Copyright_xml – notice: 2022, Posted by Cold Spring Harbor Laboratory
DBID NPM
7X8
FX.
DOI 10.1101/2022.09.12.507614
DatabaseName PubMed
MEDLINE - Academic
bioRxiv
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: FX.
  name: bioRxiv
  url: https://www.biorxiv.org/
  sourceTypes: Open Access Repository
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2692-8205
Edition 1.1
ExternalDocumentID 2022.09.12.507614v1
36263060
Genre Preprint
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: HHSN272201400008C
– fundername: NIAID NIH HHS
  grantid: R01 AI157155
– fundername: NIAID NIH HHS
  grantid: 75N93019C00051
– fundername: NIAID NIH HHS
  grantid: 75N93021C00014
GroupedDBID 8FE
8FH
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BBNVY
BENPR
BHPHI
CCPQU
HCIFZ
LK8
M7P
NPM
NQS
PHGZM
PHGZT
PIMPY
PQGLB
PROAC
RHI
7X8
FX.
ID FETCH-LOGICAL-b2534-607e645f249a3fa8c2ec6c21dd484aaab6c55a674f918f098f259028b22f11ef3
IEDL.DBID FX.
ISSN 2692-8205
IngestDate Tue Jan 07 18:55:06 EST 2025
Fri Jul 11 10:08:09 EDT 2025
Mon Jul 21 06:07:58 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
License This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-b2534-607e645f249a3fa8c2ec6c21dd484aaab6c55a674f918f098f259028b22f11ef3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Working Paper/Pre-Print-1
ObjectType-Feature-3
content type line 23
Competing Interest Statement: M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and Moderna. G.-Y.C., G.S.-J., A.N., K.W., D.L., D.M.B., L.A., H.J., P.M., N.J.A., A.C., S.E. and D.K.E. are employees of and shareholders in Moderna Inc.
ORCID 0000-0002-8791-3165
OpenAccessLink https://www.biorxiv.org/content/10.1101/2022.09.12.507614
PMID 36263060
PQID 2726924074
PQPubID 23479
PageCount 39
ParticipantIDs biorxiv_primary_2022_09_12_507614
proquest_miscellaneous_2726924074
pubmed_primary_36263060
PublicationCentury 2000
PublicationDate 2022-Sep-13
20220913
PublicationDateYYYYMMDD 2022-09-13
PublicationDate_xml – month: 09
  year: 2022
  text: 2022-Sep-13
  day: 13
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle bioRxiv
PublicationTitleAlternate bioRxiv
PublicationYear 2022
Publisher Cold Spring Harbor Laboratory
Publisher_xml – name: Cold Spring Harbor Laboratory
References 36265510 - Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8
Rathe (2022.09.12.507614v1.3) 2020
Choi (2022.09.12.507614v1.16) 2021; 27
Kaplonek (2022.09.12.507614v1.31) 2022; 55
Amanat (2022.09.12.507614v1.44) 2021; 184
Chen (2022.09.12.507614v1.37) 2021
Qi, Liu, Wang, Zhang (2022.09.12.507614v1.5) 2022; 23
Branche (2022.09.12.507614v1.18) 2022
Halfmann (2022.09.12.507614v1.21) 2022
Caserta (2022.09.12.507614v1.15) 2022
Tseng (2022.09.12.507614v1.9) 2022; 28
Nelson (2022.09.12.507614v1.40) 2020; 6
Ying (2022.09.12.507614v1.19) 2021
Flemming (2022.09.12.507614v1.33) 2022; 22
Letko, Marzi, Munster (2022.09.12.507614v1.2) 2020; 5
Zhang (2022.09.12.507614v1.25) 2022; 11
Plante (2022.09.12.507614v1.38) 2020
Ying (2022.09.12.507614v1.12) 2022; 185
Jackson (2022.09.12.507614v1.47) 2020; 383
Imai (2022.09.12.507614v1.39) 2020; 117
Whitt (2022.09.12.507614v1.46) 2010; 169
Lee (2022.09.12.507614v1.23) 2022
Case, Bailey, Kim, Chen, Diamond (2022.09.12.507614v1.48) 2020; 548
Iketani (2022.09.12.507614v1.7) 2022; 604
Du (2022.09.12.507614v1.28) 2022; 94
Pajon (2022.09.12.507614v1.11) 2022
Rössler, Knabl, Laer, Kimpel (2022.09.12.507614v1.24) 2022
Errico, Adams, Fremont (2022.09.12.507614v1.4) 2022; 154
Wang (2022.09.12.507614v1.6) 2022; 608
Elliott (2022.09.12.507614v1.10) 2022; 375
Krause (2022.09.12.507614v1.1) 2021; 385
Deng (2022.09.12.507614v1.26) 2022; 7
Ding (2022.09.12.507614v1.27) 2022
Cobb (2022.09.12.507614v1.35) 2022; 3
Zang (2022.09.12.507614v1.36) 2020; 5
Gagne (2022.09.12.507614v1.13) 2022; 185
Khoury (2022.09.12.507614v1.20) 2021; 27
Stadlbauer (2022.09.12.507614v1.43) 2020; 57
VanBlargan (2022.09.12.507614v1.45) 2021
Corbett (2022.09.12.507614v1.41) 2020; 586
Tarke (2022.09.12.507614v1.34) 2022; 185
Gorman (2022.09.12.507614v1.32) 2021; 2
Khoury (2022.09.12.507614v1.30) 2022
Chalkias (2022.09.12.507614v1.17) 2022
Chalkias (2022.09.12.507614v1.14) 2022
Uraki (2022.09.12.507614v1.22) 2022; 607
Pavot (2022.09.12.507614v1.29) 2022; 13
Hassett (2022.09.12.507614v1.42) 2019; 15
Andrews (2022.09.12.507614v1.8) 2022
References_xml – reference: 36265510 - Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8
– volume: 586
  start-page: 567
  year: 2020
  end-page: 571
  ident: 2022.09.12.507614v1.41
  article-title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
  publication-title: Nature
– volume: 57
  start-page: e100
  year: 2020
  ident: 2022.09.12.507614v1.43
  article-title: SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup
  publication-title: Curr Protoc Microbiol
– volume: 385
  start-page: 179
  year: 2021
  end-page: 186
  ident: 2022.09.12.507614v1.1
  article-title: SARS-CoV-2 Variants and Vaccines
  publication-title: N Engl J Med
– volume: 185
  start-page: 847
  year: 2022
  end-page: 859
  ident: 2022.09.12.507614v1.34
  article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron
  publication-title: Cell
– year: 2020
  ident: 2022.09.12.507614v1.3
  article-title: SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing
  publication-title: J Infect Dis
– year: 2022
  ident: 2022.09.12.507614v1.17
  article-title: Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster Vaccine
  publication-title: Research square
– volume: 5
  start-page: 562
  year: 2020
  end-page: 569
  ident: 2022.09.12.507614v1.2
  article-title: Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses
  publication-title: Nature microbiology
– year: 2022
  ident: 2022.09.12.507614v1.8
  article-title: Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
  publication-title: N Engl J Med
– year: 2021
  ident: 2022.09.12.507614v1.37
  article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
  publication-title: Nat Med
– volume: 608
  start-page: 603
  year: 2022
  end-page: 608
  ident: 2022.09.12.507614v1.6
  article-title: Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5
  publication-title: Nature
– volume: 185
  start-page: 1556
  year: 2022
  end-page: 1571.e1518
  ident: 2022.09.12.507614v1.13
  article-title: mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
  publication-title: Cell
– volume: 548
  start-page: 39
  year: 2020
  end-page: 48
  ident: 2022.09.12.507614v1.48
  article-title: Growth, detection, quantification, and inactivation of SARS-CoV-2
  publication-title: Virology
– volume: 607
  start-page: 119
  year: 2022
  end-page: 127
  ident: 2022.09.12.507614v1.22
  article-title: Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
  publication-title: Nature
– volume: 22
  start-page: 146
  year: 2022
  ident: 2022.09.12.507614v1.33
  article-title: Cross reactive T cells hold up against Omicron
  publication-title: Nat Rev Immunol
– year: 2022
  ident: 2022.09.12.507614v1.30
  article-title: Predicting the efficacy of variant-modified COVID-19 vaccine boosters
  publication-title: medRxiv : the preprint server for health sciences, 2022.2008.2025.22279237
– volume: 6
  start-page: eaaz6893
  year: 2020
  ident: 2022.09.12.507614v1.40
  article-title: Impact of mRNA chemistry and manufacturing process on innate immune activation
  publication-title: Science advances
– year: 2022
  ident: 2022.09.12.507614v1.14
  article-title: A Bivalent Omicron-containing Booster Vaccine Against Covid-19
  publication-title: medRxiv : the preprint server for health sciences, 2022.2006.2024.22276703
– year: 2022
  ident: 2022.09.12.507614v1.24
  article-title: Neutralization profile of Omicron variant convalescent individuals
  publication-title: medRxiv : the preprint server for health sciences, 2022.2002.2001.22270263
– year: 2022
  ident: 2022.09.12.507614v1.23
  article-title: Omicron-specific mRNA vaccine induced potent neutralizing antibody against Omicron but not other SARS-CoV-2 variants
  publication-title: bioRxiv, 2022.2001.2031.478406
– volume: 117
  start-page: 16587
  year: 2020
  end-page: 16595
  ident: 2022.09.12.507614v1.39
  article-title: Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development
  publication-title: Proc Natl Acad Sci U S A
– year: 2021
  ident: 2022.09.12.507614v1.19
  article-title: Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
  publication-title: Sci Transl Med, eabm3302
– volume: 55
  start-page: 355
  year: 2022
  end-page: 365
  ident: 2022.09.12.507614v1.31
  article-title: mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern
  publication-title: Immunity
– volume: 11
  year: 2022
  ident: 2022.09.12.507614v1.25
  article-title: A Heterologous V-01 or Variant-Matched Bivalent V-01D-351 Booster following Primary Series of Inactivated Vaccine Enhances the Neutralizing Capacity against SARS-CoV-2 Delta and Omicron Strains
  publication-title: Journal of clinical medicine
– volume: 604
  start-page: 553
  year: 2022
  end-page: 556
  ident: 2022.09.12.507614v1.7
  article-title: Antibody evasion properties of SARS-CoV-2 Omicron sublineages
  publication-title: Nature
– volume: 185
  start-page: 1572
  year: 2022
  end-page: 1587
  ident: 2022.09.12.507614v1.12
  article-title: Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
  publication-title: Cell
– volume: 169
  start-page: 365
  year: 2010
  end-page: 374
  ident: 2022.09.12.507614v1.46
  article-title: Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines
  publication-title: J Virol Methods
– volume: 2
  start-page: 100405
  year: 2021
  ident: 2022.09.12.507614v1.32
  article-title: Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
  publication-title: Cell reports. Medicine
– volume: 27
  start-page: 1205
  year: 2021
  end-page: 1211
  ident: 2022.09.12.507614v1.20
  article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
  publication-title: Nat Med
– volume: 7
  start-page: 124
  year: 2022
  ident: 2022.09.12.507614v1.26
  article-title: Sequential immunizations confer cross-protection against variants of SARS-CoV-2, including Omicron in Rhesus macaques
  publication-title: Signal transduction and targeted therapy
– volume: 28
  start-page: 1063
  year: 2022
  end-page: 1071
  ident: 2022.09.12.507614v1.9
  article-title: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
  publication-title: Nat Med
– volume: 94
  start-page: 4287
  year: 2022
  end-page: 4293
  ident: 2022.09.12.507614v1.28
  article-title: A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity
  publication-title: J Med Virol
– volume: 3
  start-page: 188
  year: 2022
  end-page: 203
  ident: 2022.09.12.507614v1.35
  article-title: A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques
  publication-title: Med (New York, N.Y.)
– volume: 5
  year: 2020
  ident: 2022.09.12.507614v1.36
  article-title: TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes
  publication-title: Sci Immunol
– volume: 184
  start-page: 3936
  year: 2021
  end-page: 3948
  ident: 2022.09.12.507614v1.44
  article-title: SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
  publication-title: Cell
– year: 2022
  ident: 2022.09.12.507614v1.11
  article-title: SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
  publication-title: N Engl J Med
– year: 2022
  ident: 2022.09.12.507614v1.15
  article-title: White-tailed deer (<em>Odocoileus virginianus</em>) may serve as a wildlife reservoir for nearly extinct SARS-CoV-2 variants of concern
  publication-title: bioRxiv, 2022.2009.2002.506368
– year: 2020
  ident: 2022.09.12.507614v1.38
  article-title: Spike mutation D614G alters SARS-CoV-2 fitness
  publication-title: Nature
– volume: 15
  start-page: 1
  year: 2019
  end-page: 11
  ident: 2022.09.12.507614v1.42
  article-title: Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
  publication-title: Molecular therapy. Nucleic acids
– volume: 23
  start-page: 1008
  year: 2022
  end-page: 1020
  ident: 2022.09.12.507614v1.5
  article-title: The humoral response and antibodies against SARS-CoV-2 infection
  publication-title: Nat Immunol
– volume: 27
  start-page: 2025
  year: 2021
  end-page: 2031
  ident: 2022.09.12.507614v1.16
  article-title: Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis
  publication-title: Nat Med
– year: 2022
  ident: 2022.09.12.507614v1.27
  article-title: Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategies
  publication-title: J Med Virol
– year: 2021
  ident: 2022.09.12.507614v1.45
  article-title: A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope
  publication-title: Immunity
– year: 2022
  ident: 2022.09.12.507614v1.18
  article-title: SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary Analyses
  publication-title: medRxiv : the preprint server for health sciences, 2022.2007.2012.22277336
– year: 2022
  ident: 2022.09.12.507614v1.21
  article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
  publication-title: Nature
– volume: 383
  start-page: 1920
  year: 2020
  end-page: 1931
  ident: 2022.09.12.507614v1.47
  article-title: An mRNA Vaccine against SARS-CoV-2 - Preliminary Report
  publication-title: N Engl J Med
– volume: 154
  start-page: 1
  year: 2022
  end-page: 69
  ident: 2022.09.12.507614v1.4
  article-title: Antibody-mediated immunity to SARS-CoV-2 spike
  publication-title: Adv Immunol
– volume: 375
  start-page: 1406
  year: 2022
  end-page: 1411
  ident: 2022.09.12.507614v1.10
  article-title: Rapid increase in Omicron infections in England during December 2021: REACT-1 study
  publication-title: Science
– volume: 13
  start-page: 1699
  year: 2022
  ident: 2022.09.12.507614v1.29
  article-title: Protein-based SARS-CoV-2 spike vaccine booster increases cross-neutralization against SARS-CoV-2 variants of concern in non-human primates
  publication-title: Nat Commun
SSID ssj0002961374
Score 1.8092924
SecondaryResourceType preprint
Snippet The emergence of SARS-CoV-2 variants in the Omicron lineage with large numbers of substitutions in the spike protein that can evade antibody neutralization has...
SourceID biorxiv
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
SubjectTerms Microbiology
Title Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
URI https://www.ncbi.nlm.nih.gov/pubmed/36263060
https://www.proquest.com/docview/2726924074
https://www.biorxiv.org/content/10.1101/2022.09.12.507614
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT8MwDI5gExI33u8pSFwzNVmatsdtYkJIDLQxtFvltgn0sBT2QPDvcdoycQCJa5SXXNf5vtixCbniaOEUSGDa-ClDBG5YhMiA6TBMTSZEkkTucfLdUN1M5O3Un_4o9eXCKpO8mH_k76Uf3wVso_Wtfm6PO64uXGJSLtq-o-BykzRRpaSr2jCYttfXKyLCcyqQtR_z15GIeOuV_kaX5Skz2CHNB3jV812yoe0e2arKRH7uk7dejvqA-6Pj7mjM-sUTE3Q2GnbpO6TOMb6guXXob6EpMlzIli-0MNTqVXmNUT20pGAzWmdloPAMOeJCiuiP9rptn97PXGCexQlRIe3ygEwG14_9G1aXSmCJ8DuSKS_QSvoGyRR0DISp0KlKBc8yGUoASFTq-6ACaSIeGi8KjSjztiRCGM616RyShi2sPiYUGZZUgIYwc85eI3Es4BeTIEKTpIE8IZe12OLXKiFG7EQbe1HMRVyJFvt8CzRGdXU-CLC6WC1iEQgVORaJfY4qSa-nKTPjeMo7_ccKZ2TbtbnIDd45J43lfKUvEB4skxZp9q6HD6NWqRBfgCS0qQ
linkProvider Cold Spring Harbor Laboratory Press
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9swDBbWFkN7a9c9unWbBuyqwFJk2T4mQYNsS7IiSYfcDNqWOh8id3kU678vaXs5rUDP1sOgaen7SOoTY18lrnAGNAjrwlwgAnciQWQgbBznrlAqyxI6nDyZmtGN_r4Ml23AbdOWVWZltf5b3td5fCrYxtW3-bkDSVxdkTCpVJ2QKLjuUJj6gB2R0BmVdA2XnX2MRSW4WUW6TWb-tzvC3na6pyFmvdUMT9nRNdzZ9Rl7Yf0r9rK5K_LhnP3pl-gU-JJ83pvNxaD6JRRfzaY9fg85Zcc3vPQEATeWI82FYvubV457u6tjGc1pSw6-4K00A4dbKBEccoSAvN_rhPzniqrzPA6IXum3r9nN8GoxGIn2vgSRqbCrhQkia3TokFFB10GcK5ubXMmi0LEGgMzkYQgm0i6RsQuS2KlavCVTyklpXfcNO_SVt-8YR5qlDeBqWFDG12nsC_jZNKjYZXmkL9iX1mzpXaOKkZJp0yBJpUob02KbfwZN0WcpEQHeVrtNqiJlEqKS2OZtY-n9MLU8TmCC98-Y4TM7Hi0m43T8bfrjAzuh51TKIbuX7HC73tmPiBe22afaKR4BICm35g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwELYoiIpbgbbQ8jBSr45ir-Mkx-Wx4rkgHtXeokliQw44230g-PfMJAH1QKWe44yj8WT8fZ6HGfsl0cMZ0CCsiwqBCNyJFJGBsElSuFKpPE-pOPliaI7v9OkoGv1VC0NplXlVT56rpyaOTwnb6H3bnzuUxNUVNSaVKoiIguuAjqmDcek-sSVqdkaWPRgF7-csKsUNK9ZdQPNDEQh9uyn_DTOb7WbwhS1dwdhOVtmC9Wtsub0v8mWd_dmv0DDwQ_lN__pGHNS_heKP18M-f4KCIuRTXnmCgVPLkepCOXvgtePezpvzjLbikoMvedeegcM9VAgQOcJAvt8PIn75SBl6HgWiZfrZV3Y3OLo9OBbdnQkiV1FPCxPG1ujIIauCnoOkULYwhZJlqRMNALkpoghMrF0qExemiVNNA5dcKSeldb1vbNHX3m4wjlRLG0CPWFLU12l8F3DpNKjE5UWsN9lep7Zs3HbGyEi1WZhmUmWtanHMm0IztFsKRoC39XyaqViZlOgkjvneavpdTNMiJzThj_-YYZd9vjocZOcnw7OfbIUeUzaH7G2xxdlkbrcRMszyncYmXgHw_rj3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bivalent+SARS-CoV-2+mRNA+vaccines+increase+breadth+of+neutralization+and+protect+against+the+BA.5+Omicron+variant&rft.jtitle=bioRxiv&rft.au=Scheaffer%2C+Suzanne+M&rft.au=Lee%2C+Diana&rft.au=Whitener%2C+Bradley&rft.au=Ying%2C+Baoling&rft.date=2022-09-13&rft.issn=2692-8205&rft.eissn=2692-8205&rft_id=info:doi/10.1101%2F2022.09.12.507614&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-8205&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-8205&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-8205&client=summon